{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:00:44Z","timestamp":1793048444756,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017547","name":"Jiangsu Association for Science and Technology","doi-asserted-by":"publisher","award":["JSKJZK2023041"],"award-info":[{"award-number":["JSKJZK2023041"]}],"id":[{"id":"10.13039\/501100017547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.yebeh.2023.109283","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T13:24:01Z","timestamp":1686576241000},"page":"109283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Mining and analysis of adverse drug reactions associated with perampanel based on FAERS database"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-6334","authenticated-orcid":false,"given":"Pengcheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-1384","authenticated-orcid":false,"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.yebeh.2023.109283_b0005","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2023.109283_b0010","series-title":"Epilepsy: a public health imperative","author":"WHO","year":"2019"},{"issue":"10172","key":"10.1016\/j.yebeh.2023.109283_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109283_b0020","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2174\/1570159X18666200831154658","article-title":"Targeting ionotropic glutamate receptors in the treatment of epilepsy","volume":"19","author":"Celli","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.yebeh.2023.109283_b0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ane.12099","article-title":"AMPA receptors as a molecular target in epilepsy therapy","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109283_b0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/biom10030464","article-title":"Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors","volume":"10","author":"Hanada","year":"2020","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.yebeh.2023.109283_b0035","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14740338.2022.2134856","article-title":"Safety evaluation of perampanel as monotherapy or first adjunctive therapy in patients with epilepsy","volume":"21","author":"Wheless","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.yebeh.2023.109283_b0040","series-title":"Epilepsies in children, young people and adults","author":"NICE","year":"2022"},{"key":"10.1016\/j.yebeh.2023.109283_b0045","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2147\/TCRM.S316476","article-title":"Optimal use of perampanel in asian patients with epilepsy: expert opinion","volume":"17","author":"Chinvarun","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.yebeh.2023.109283_b0050","article-title":"Healthcare utilization and associated costs following initiation of perampanel in patients with epilepsy","volume":"110","author":"Morgan","year":"2020","journal-title":"EpilepsyBehav: E&B"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109283_b0055","doi-asserted-by":"crossref","first-page":"364","DOI":"10.21037\/atm-22-994","article-title":"Cost-effectiveness of perampanel as an adjunctive treatment for uncontrolled focal seizures in pediatric patients: a Chinese perspective","volume":"10","author":"Hu","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.yebeh.2023.109283_b0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.yebeh.2018.06.002","article-title":"Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective","volume":"86","author":"Tremblay","year":"2018","journal-title":"Epilepsy Behav: E&B"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2023.109283_b0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/epi.14456","article-title":"Perampanel: Does it have broad-spectrum potential?","volume":"60","author":"Potschka","year":"2019","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109283_b0070","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10072-022-05867-6","article-title":"Perampanel for amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"43","author":"Turalde","year":"2022","journal-title":"Neurol Sci: Official J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109283_b0075","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00415-017-8681-y","article-title":"Efficacy and safety of perampanel in Parkinson\u2019s disease. A systematic review with meta-analysis","volume":"265","author":"Lattanzi","year":"2018","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109283_b0080","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/mds.28558","article-title":"Perampanel Inhibits \u03b1-synuclein transmission in parkinson\u2019s disease models","volume":"36","author":"Ueda","year":"2021","journal-title":"Movement Disorders: Official J Movement Disorder Soc"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109283_b0085","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/epi.14044","article-title":"Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307","volume":"59","author":"Krauss","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109283_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108407","article-title":"Long-term efficacy and safety of perampanel as a first add-on therapy in patients with focal epilepsy: Three-year extension study","volume":"125","author":"Im","year":"2021","journal-title":"Epilepsy Behav: E&B"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109283_b0095","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bcp.12951","article-title":"Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials","volume":"82","author":"Majid","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2023.109283_b0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.eplepsyres.2018.12.003","article-title":"Potential protein-binding displacement interactions with perampanel: an in vitro analysis","volume":"149","author":"Gidal","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2023.109283_b0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.eplepsyres.2017.04.018","article-title":"Effect of enzyme inhibition on perampanel pharmacokinetics: why study design matters","volume":"134","author":"Gidal","year":"2017","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109283_b0110","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3988\/jcn.2022.18.6.653","article-title":"Effects of perampanel on seizure control, cognition, behavior, and psychological status in patients with epilepsy: a systematic review","volume":"18","author":"Fong","year":"2022","journal-title":"J Clin Neurol (Seoul, Korea)"},{"key":"10.1016\/j.yebeh.2023.109283_b0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.seizure.2021.12.001","article-title":"The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy","volume":"94","author":"Witt","year":"2022","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109283_b0120","first-page":"224","article-title":"Effects of antiepileptic drugs on sleep architecture parameters in adults","volume":"15","author":"Carvalho","year":"2022","journal-title":"Sleep Sci (Sao Paulo, Brazil)"},{"key":"10.1016\/j.yebeh.2023.109283_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107515","article-title":"Positive and negative effects of perampanel treatment on psychiatric and behavioral symptoms in adult patients with epilepsy","volume":"117","author":"Hasegawa","year":"2021","journal-title":"Epilepsy Behav: E&B"},{"key":"10.1016\/j.yebeh.2023.109283_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108493","article-title":"Differences in aggression as psychiatric side effect of levetiracetam and perampanel in patients with epilepsy","volume":"126","author":"Kawai","year":"2022","journal-title":"Epilepsy Behav: E&B"},{"key":"10.1016\/j.yebeh.2023.109283_b0135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.seizure.2020.01.021","article-title":"Perampanel effect on sleep architecture in patients with epilepsy","volume":"76","author":"Rocamora","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109283_b0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yebeh.2016.08.004","article-title":"Sleep quality and daytime sleepiness in patients treated with adjunctive perampanel for focal seizures","volume":"63","author":"Toledo","year":"2016","journal-title":"Epilepsy Behav: E&B"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2023.109283_b0145","article-title":"Movement disorders associated with antiseizure medications: A systematic review","volume":"131","author":"Zhou","year":"2022","journal-title":"Epilepsy Behav: E&B"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109283_b0150","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40263-022-00937-x","article-title":"Antiseizure Drugs and Movement Disorders","volume":"36","author":"S\u00e1enz-Farret","year":"2022","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109283_b0155","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/08830738221089742","article-title":"Movement disorders secondary to novel antiseizure medications in pediatric populations: a systematic review and meta-analysis of risk","volume":"37","author":"Peacock","year":"2022","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2023.109283_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107514","article-title":"Effects of perampanel on cognition and quantitative electroencephalography in patients with epilepsy","volume":"115","author":"Ahn","year":"2021","journal-title":"Epilepsy Behav: E&B"},{"key":"10.1016\/j.yebeh.2023.109283_b0165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.yebeh.2018.03.029","article-title":"Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures","volume":"83","author":"Pi\u00f1a-Garza","year":"2018","journal-title":"Epilepsy Behav: E&B"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109283_b0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109283_b0175","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109283_b0180","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.yebeh.2023.109283_b0185","series-title":"Data mining and analysis of adverse reactions of ACEI drugs based on FAERS database","author":"Tan","year":"2021"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109283_b0190","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.yebeh.2023.109283_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychires.2013.05.001","article-title":"Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects","volume":"47","author":"Coccaro","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"23","key":"10.1016\/j.yebeh.2023.109283_b0200","doi-asserted-by":"crossref","first-page":"19388","DOI":"10.1021\/acsomega.2c01008","article-title":"Hippocampal Proteomic Analysis in Male Mice Following Aggressive Behavior Induced by Long-Term Administration of Perampanel","volume":"7","author":"Yang","year":"2022","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109283_b0205","doi-asserted-by":"crossref","first-page":"13667","DOI":"10.1038\/s41598-020-70601-1","article-title":"HLAs associated with perampanel-induced psychiatric adverse effects in a Korean population","volume":"10","author":"Jang","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109283_b0210","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1248\/bpb.b21-00954","article-title":"Association of Aggression and Antiepileptic Drugs: Analysis Using the Japanese Adverse Drug Event Report (JADER) Database","volume":"45","author":"Kawada","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.yebeh.2023.109283_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108356","article-title":"Risk factors for psychiatric adverse effects associated with perampanel therapy","volume":"124","author":"Yamamoto","year":"2021","journal-title":"Epilepsy Behav: E&B"},{"issue":"9","key":"10.1016\/j.yebeh.2023.109283_b0220","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","article-title":"Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis","volume":"78","author":"Klein","year":"2021","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109283_b0225","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00228-017-2348-6","article-title":"Perampanel-associated self-harm ideation after dosage increase","volume":"74","author":"Kheloufi","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109283_b0230","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/epi.12643","article-title":"Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307","volume":"55","author":"Krauss","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109283_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108483","article-title":"A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy","volume":"126","author":"Maguire","year":"2022","journal-title":"Epilepsy Behav: E&B"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109283_b0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11910-016-0640-y","article-title":"Practice update: review of anticonvulsant therapy","volume":"16","author":"Chong","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109283_b0245","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3345\/kjp.2018.06863","article-title":"Efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy","volume":"62","author":"Yun","year":"2019","journal-title":"Korean J Pediatr"},{"key":"10.1016\/j.yebeh.2023.109283_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107832","article-title":"Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)","volume":"117","author":"Kamitaki","year":"2021","journal-title":"Epilepsy Behav: E&B"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109283_b0255","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1017\/cjn.2020.203","article-title":"Hyperammonemic Encephalopathy Associated with Perampanel: Case Report and Discussion","volume":"48","author":"Marques","year":"2021","journal-title":"Can J Neurol Sci: Le journal canadien des sciences neurologiques"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109283_b0260","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40272-021-00448-0","article-title":"Neurocognitive effects of antiseizure medications in children and adolescents with epilepsy","volume":"23","author":"Besag","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109283_b0265","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1111\/epi.13019","article-title":"Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures","volume":"56","author":"Vazquez","year":"2015","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109283_b0270","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109283_b0275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109283_b0280","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration","volume":"24","author":"Hartnell","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.yebeh.2023.109283_b0285","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023002020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023002020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:51:06Z","timestamp":1782496266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023002020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":57,"alternative-id":["S1525505023002020"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109283","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mining and analysis of adverse drug reactions associated with perampanel based on FAERS database","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109283"}}